



Kick-Off Meeting Phase I
25 April 2014, Lyon, France

9:00 WELCOME

--- BRIEF UPDATE: WHERE DO WE STAND?

*Host: I. Ray-Coquard / CLB,
Coordinator: N. Concin / IMU*

9:10 Overall GANNET53 project up-date

N. Concin / IMU

9:20 WP1 – Management

G. Klaming / OncoLab

9:30 WP2 – Status quo: Preparations for clinical trials

R. Berger / IMU, A-AGO

--- GANETESPIB NEWS

9:45 Safety up-date, combination data with Paclitaxel and more news

*I. El-Hariry / Synta
Pharmaceuticals, EAB*

--- PHASE I

10:10 WP3 – Phase I protocol review

I. Ray-Coquard / CLB

10:40 Critical issues and risks in our Phase I trial

P. Cassier / CLB

11:00 COFFEE BREAK

--- SAFETY

11:30 Adverse events to be expected in the GANNET53 trial

S. Mahner / UKE, AGO

12:00 Safety management

G. Elser / AGO

12:30 Quality management and monitoring

S. Embacher-Aichhorn / IMU

13:00 LUNCH

14:00 eCRF including demonstration

I. Braicu / CHARITE, NOGGO

14:30 Communication plan

B. Votan / GINECO

--- OF IMPORTANCE

15:00 WP4 – Phase II: PK analysis

I. Vergote / KU Leuven

15:30 Histologic characteristics of eligible EOC subtypes

S. Darb-Esfahani / CHARITE

15:50 Resume and closing remarks of the national trial group leaders and Leuven

*C. Marth / A-AGO
I. Ray-Coquard / GINECO
I. Braicu / NOGGO
S. Mahner / AGO
I. Vergote / KU Leuven*

16:00 CLOSURE

*I. Ray-Coquard / CLB
N. Concin / IMU*

